(SACRAMENTO, Calif.) – Experts from UC Davis Health System will share the latest research about regenerative medicine, with a focus on chronic pain and the promise of stem cell therapies,
Originally posted here:
The promise of stem cell therapies forum
WALTHAM, Mass.–(BUSINESS WIRE)–
Histogenics Corporation, a privately held, regenerative medicine company, today announced that President and Chief Executive Officer Patrick O’Donnell will present at the upcoming Canaccord Genuity Musculoskeletal Conference on February 7th at 3:30pm PT at the Parc 55 Wyndham in San Francisco. Mr. O’Donnell will discuss the Company’s lead product candidates, including NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions and VeriCart™, a three-dimensional cartilage matrix to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial and will be the subject of an oral presentation at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), which is also taking place in San Francisco from February 7th-11th.
About Histogenics
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company Prochon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit www.histogenics.com.
Continue reading here:
Histogenics Corporation to Present at Canaccord Genuity Musculoskeletal Conference
EXTON, Pa., Feb. 2, 2012 /PRNewswire/ — Kensey Nash Corporation (NASDAQ: KNSY – News), a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported …
See the rest here:
Kensey Nash Reports Second Quarter Fiscal Year 2012 Financial Results
18-11-2011 14:04 Rehabilitation Medicine Update, New “Regenerative Medical Rehabilitation” Management Procedure.The Prospective Role Of The Trans Cranial Magnetic Stimulation TCMS (TMS) Technique In Brain Regeneration And Re-education. According To The USA — FDA In 2009 : Transcranial Magnetic Stimulation Is A Procedure That Uses Magnetic Fields To Stimulate Nerve Cells In The Brain To Improve Symptoms Of Depression. TCMS – Universal Applicable Range * Applicable For A Wide Range Of Patients In Need Of Brain Functional Rehabilitation Ischemic Cerebrovascular Incidences : Cerebral thrombosis?lacunar infarction?vertebrobasilar insufficiency, Cerebrovascular insufficiency?cerebral arteriosclerosis?. * Brain Diseases: Functional rehabilitation on children with cerebral palsy, Senile Dementia?Parkinsonism. Craniocerebral injury?convalescence of cerebral infarction?after Craniocerebral Operation. Epilepsy?encephalatrophy? * Psychiosis: Depression?Neuropathic headache?Insomnia?Schizophrenia?
Here is the original post:
Dr Aziz Denian Transcranial Magnetic Stimulation 2011 ForVideoRecordShrinked2 pptx – Video
Speakers include Advanced Cell Technology, Athersys, Cytori, Dendreon,
Genzyme-Sanofi, Johnson & Johnson, Mesoblast and Shire
WASHINGTON, DC, January 5, 2012 – The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine (RM) community, today released the agenda for its second annual State of the Industry Briefing and RM Insight Track. The meeting will take place on January 10 – 11, 2012 at the Park 55 Wyndham in San Francisco.
The Regenerative Medicine State of the Industry Briefing will focus on recent developments and the future outlook for regenerative medicine, cell therapy and other advanced therapeutics. A full day of panels focused on several disease areas will follow the briefing as part of the Regenerative Medicine Insight track at the Biotech Showcase 2012. The panels will be moderated by key analysts in the sector. Please see agenda below:
Tuesday, January 10, 2012
8:00 – 9:30 AM Regenerative Medicine State of the Industry Briefing
Gil Van Bokkelen, CEO, Athersys (Moderator) Silviu Itescu, CEO, Mesoblast Tim Mayleben, CEO of Aaastrom Gary Rabin, CEO, Advanced Cell Technology Robin Smith, CEO, NeoStem Leanna Caron, VP & GM of Cell Therapy & Regenerative Medicine, Genzyme-Sanofi Ed Field, COO, Aldagen Jay Seigal, CBO, Johnson & Johnson Dean Tozer, Senior VP of Corporate Development, ABH-Shire Susan Solomon, CEO, New York Stem Cell Foundation
Therapeutic Focus Panels
9:30 – 10:45 AM Cardiovascular, AMI and PAD—Part 1
Analyst: Jason Butler, JMP Securities
Amorcyte, Andrew Pecora, CSO Cytori, Marc Hendrick, President Athersys, Gil Van Bokkelen, CEO Mesoblast, Silviu Itescu, CEO
10:50AM – 12:15 PM Cardiovascular, CLI and Stroke—Part 2
Analyst: Ren Benjamin, Rodman and Renshaw
Aastrom, Brian Gibson, VP Finance ReNeuron, Michael Hunt, CEO Aldagen, Ed Field, COO Tissue Genesis, Anton Krucky, CEO SanBio, Keita Mori, CEO
1:45 – 3:00 PM Neurodegenerative Disease, Ophthalmology and Spinal Injury
Analyst: Steve Brozak, WBB Securities
StemCells, Inc., Martin McGlynn, CEO NeuralStem, Richard Garr, CEO InVivo, Frank Reynolds, Chairman of the Board, CEO, CFO, Advanced Cell Technology, Gary Rabin, CEO
3:00 – 4:15 PM Renal and AutoImmune Disease
Analyst: Kai Makay, Roth Capital
Tengion, Mark Stejbach, VP, CCO Allocure, John Wirthlin, COO Tigenix, Eduardo Bravo, CEO Q Therapeutics, Deborah Eppstein, CEO
4:20 – 5:45 PM Tissue Engineering, Orthobiologics and Artificial Conduits to Wound Care and BioPrinting
Analyst: Jeffery Cohen, Ladenburg Thalmann & Co.
ISTO, Scott Gill, CFO Organovo, Keith Murphy, CEO ABH – Shire, Dean Tozer, Senior VP of Corporate Development Healthpoint, Rob Bancroft, VP, Strategic and Corporate Development Axogen, Karen Zaderej, CEO · Harvard Biosciences, David Green, CEO
Wednesday, January 11, 2012
9:00 – 10:30 AM Hematology & Immunology
Analyst: Stephen Dunn, LifeTech Capital
Dendreon, David L. Urdal, Executive VP, CSO Prima BioMed, Martin Rogers, CEO ImmunoCellular, Manish Singh, CEO Coronado, Bobby Sandage, CEO bluebird bio, Jeffrey Walsh, COO NexImmune, Ken Carter, CEO Maxcyte, Doug Doerfler, CEO
To learn more and to register for the conference, please contact Rob Margolin at (646) 201-4192. Registration is complimentary for credentialed members of the media and the investment community. The State of the Industry briefing is open to the public, but attendance at the disease panels will require registration for individuals without press or investor credentials.
About Biotech Showcase™ (Innovation – Opportunity – Collaboration):
Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of the annual JP Morgan Healthcare Conference, one of the most important healthcare industry events of the year which attracts thousands of healthcare and life science business executives to San Francisco. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group. Please visit their website for more information: www.biotechshowcase.com.
About The Alliance for Regenerative Medicine (ARM)
ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM in September 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.
Distributed by www.proactivenewsrom.com
ProActive Capital Resources Group LLC.
Read this article:
Coronado Biosciences to attend the Alliance for Regenerative Medicine Biotech conference in San Francisco
19-10-2011 18:19 Mark Walter, MD is an internationally recognized expert in the field of Regenerative Medicine. He is McGill trained (1980) and has specialized in Sports Medicine and healing sports-related injuries for over three decades. Dr. Walter has worked with many of the top teachers in the world in Regenerative Medicine and for five years he joined the staff of the Univ. of Wisconsin Medical School to help train residents and doctors in Central America. Dr. Walter is a member of the American Academy of Orthopedic Medicine and is founder of ProloMD, located in Sarasota, FL. He has a special interest in working with golf-related injuries and can be found on the web at www.PRPyourpain.com and/or ProloMD.com.
Read the original here:
Mark Walter, MD introduces Prolotherapy and PRP: The New Field of Regenerative Medicine – Video
The California Institute for Regenerative Medicine plans for a future without state support.
Read the rest here:
Stem-cell agency faces budget dilemma
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today that the Aberdeen Royal Infirmary, the largest of the Grampian University Hospitals in Scotland, has been confirmed as a site for its Phase 1/2 human clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells .
Read this article:
ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived …
"http://www.medcitynews.com/2012/01/stem-cell-therapy-company-juventas-encouraged-by-heart-failure-trial/stem-cells/"
rel="attachment wp-att-119721">
"aligncenter size-full wp-image-119721" title="stem cells" src=
"http://www.medcitynews.com/wordpress/wp-content/uploads/stem-cells.jpg"
alt="" width="375" height="500">
Regenerative medicine company
"http://www.medcitynews.com/tag/juventas-therapeutics/" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-1" id="readabilityLink-1">Juventas
Therapeutics
"readability-DoNotFootnote" style=
"color: inherit;">[1] is touting
the results from 12-month data of a phase 1 clinical trial of
heart failure patients.
At 12 months, heart failure patients treated with the company’s
stem cell therapy showed “significant” improvements in two key
measures — a six-minute distance-walking test, as well as the
"http://qol.thoracic.org/sections/instruments/ko/pages/mlwhfq.html"
onclick=
"javascript:_gaq.push(['_trackEvent','outbound-article','http://qol.thoracic.org']);"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-2" id="readabilityLink-2">Minnesota Living
with Heart Failure Questionnaire
"#readabilityFootnoteLink-2" class="readability-DoNotFootnote"
style="color: inherit;">[2], a
patient self-assessment of how heart failure affects daily
life.
Read the rest here:
Regenerative medicine company encouraged by heart failure trial
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today the dosing of an additional patient in its Phase 1/2 trial for Stargardt’s macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells .
Read more from the original source:
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …
30-11-2011 05:21 Kevin Shakesheff, University of Nottingham. Regenerative medicine: Opportunities to transform therapies
Originally posted here:
Bio-Dundee Conference 2011 – Regenerative Medicine – Video
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today that Phase 1/2 clinical data published in The Lancet as an early online publication demonstrate the safety of ACT’s human embryonic stem cell -derived retinal pigment epithelium cells for the treatment of Stargardt’s macular dystrophy and dry age-related macular degeneration .
See more here:
ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients
Regenerative medicine company KeraNetics, whose biomaterials research into healing damaged tissue is already in the U.S.
See the original post here:
Regenerative medicine firm KeraNetics closes in on $7M in financing
17-01-2012 15:42 Are you tired of fad diets that promise results without delivering? Then it’s time to visit the Center for Preventative and Regenerative Medicine, where patients are our number one priority. We’ll help you lose weight the healthy way, and keep it off
Read the rest here:
Center for Preventative and Regenerative Medicine – Video
TAP Biosystems in Cambridge is collaborating with a major regenerative medicine company to develop a custom manufacturing system to ensure the consistent quality of the customer’s innovative cell-based therapy. Read more…
Go here to read the rest:
Regenerative medicine firm TAPs Cambridge expertise
A study exploring lung repair and tissue regeneration to fight lung diseases by a team at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia has received a $2.5 million grant. The grant was awarded by the National Heart, Lung, and Blood Institute’s Lung Repair and Regeneration Consortium to six institutions, including Penn,
Here is the original post:
Regenerative medicine for lung disease focus of $2.5 million Penn grant
AUSTIN, Texas , Jan. 17, 2012 /PRNewswire/ – SpineSmith , a Celling Biosciences company that designs, develops and markets innovative technologies in the field of regenerative medicine, is pleased to …
See the article here:
SpineSmith Adds Talented Scientist to Research and Development Team
AxoGen, Inc.
Originally posted here:
Avance Nerve Graft Clinical Results Published
09-01-2012 16:22
The rest is here:
How It’s Made Season 17, Episode 1 Decorative Sombreros, Salad Dressings, Cap Guns, Regenerative Medicine – Video
A newly released form of Regenerative Medicine brings this exciting therapy to all small pets and horses. OsteoBioScaff™ creates an immediate, and readily available, therapy choice for veterinarians
Read more here:
Regenerative Medicine for Pets has Changed for the Better! Now Available “OsteoBioScaff™”